Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia
- PMID: 14754783
- DOI: 10.1176/appi.ajp.161.2.332
Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia
Abstract
Objective: This study evaluated the effectiveness of a supervised benzodiazepine taper, singly and combined with cognitive behavior therapy, for benzodiazepine discontinuation in older adults with chronic insomnia.
Method: Seventy-six older adult outpatients (38 women, 38 men; mean age of 62.5 years) with chronic insomnia and prolonged use (mean duration of 19.3 years) of benzodiazepine medication for sleep were randomly assigned for a 10-week intervention consisting of a supervised benzodiazepine withdrawal program (N=25), cognitive behavior therapy for insomnia (N=24), or supervised withdrawal plus cognitive behavior therapy (N=27). Follow-up assessments were conducted at 3 and 12 months. The main outcome measures were benzodiazepine use, sleep parameters, and anxiety and depressive symptoms.
Results: All three interventions produced significant reductions in both the quantity (90% reduction) and frequency (80% reduction) of benzodiazepine use, and 63% of the patients were drug-free within an average of 7 weeks. More patients who received medication taper plus cognitive behavior therapy (85%) were benzodiazepine-free after the initial intervention, compared to those who received medication taper alone (48%) and cognitive behavior therapy alone (54%). The patients in the two groups that received cognitive behavior therapy perceived greater subjective sleep improvements than those who received medication taper alone. Polysomnographic data showed an increase in the amount of time spent in stages 3 and 4 sleep and REM sleep and a decrease in total sleep time across all three conditions from baseline to posttreatment. Initial benzodiazepine reductions were well maintained up to the 12-month follow-up, and sleep improvements became more noticeable over this period. No significant withdrawal symptoms or adverse events were associated with benzodiazepine tapering.
Conclusions: A structured, time-limited intervention is effective in assisting chronic users of benzodiazepine medication to discontinue or reduce their use of medication. The addition of cognitive behavior therapy alleviates insomnia, but sleep improvements may become noticeable only after several months of benzodiazepine abstinence.
Similar articles
-
Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse.Behav Res Ther. 2005 Jan;43(1):1-14. doi: 10.1016/j.brat.2003.12.002. Behav Res Ther. 2005. PMID: 15531349
-
Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial.CMAJ. 2003 Nov 11;169(10):1015-20. CMAJ. 2003. PMID: 14609970 Free PMC article. Clinical Trial.
-
Self-efficacy and compliance with benzodiazepine taper in older adults with chronic insomnia.Health Psychol. 2005 May;24(3):281-7. doi: 10.1037/0278-6133.24.3.281. Health Psychol. 2005. PMID: 15898864 Clinical Trial.
-
Withdrawing benzodiazepines in primary care.CNS Drugs. 2009;23(1):19-34. doi: 10.2165/0023210-200923010-00002. CNS Drugs. 2009. PMID: 19062773 Review.
-
Benzodiazepine dependence.Aust Fam Physician. 2004 Nov;33(11):923-6. Aust Fam Physician. 2004. PMID: 15584332 Review.
Cited by
-
Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial.JAMA Intern Med. 2024 Oct 7:e245020. doi: 10.1001/jamainternmed.2024.5020. Online ahead of print. JAMA Intern Med. 2024. PMID: 39374004
-
Integrating the Memory Support Intervention into the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C): can improving memory for treatment in midlife and older adults improve patient outcomes? Study protocol for a randomized controlled trial.Trials. 2024 Oct 3;25(1):650. doi: 10.1186/s13063-024-08468-0. Trials. 2024. PMID: 39363383 Free PMC article.
-
Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial.JAMA Psychiatry. 2024 Sep 18:e242731. doi: 10.1001/jamapsychiatry.2024.2731. Online ahead of print. JAMA Psychiatry. 2024. PMID: 39292452
-
Benzodiazepine Discontinuation and Mortality Among Patients Receiving Long-Term Benzodiazepine Therapy.JAMA Netw Open. 2023 Dec 1;6(12):e2348557. doi: 10.1001/jamanetworkopen.2023.48557. JAMA Netw Open. 2023. PMID: 38117495 Free PMC article.
-
Perspectives on increasing the impact and reach of CBT-I.Sleep. 2023 Dec 11;46(12):zsad168. doi: 10.1093/sleep/zsad168. Sleep. 2023. PMID: 37903637 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
